The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

"For the first time, we have a disease-modifying treatment that can interfere with the biology of Alzheimer's disease and ...

A pause to NIH funding has researchers scrambling for contingency plans at the University of Washington’s Alzheimer’s Disease ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with ...

The situation has left Gilbert’s neurologist, Dr. Thomas Grabowski, confused and scrambling. What will happen to patient care and the brains banked for research at Harborview? “We’ve gone ...

Andrea Gilbert thought she knew what would happen to her brain. The 79-year-old retired attorney, who has Alzheimer’s disease and receives care at Harborview Medical Center in Seattle, agreed to ...

"We’ve gone through a bunch of contingency planning," University of Washington’s Alzheimer’s Disease Research Center director Thomas Grabowski told NBC, referring to grant decisions slowing to a crawl ...

We are writing as leaders of research centers at University of Washington Medicine focused on combating the effects of age and Alzheimer’s disease on quality of life. While the National Institutes of ...

Dr. Thomas Grabowski is professor of radiology and neurology in the UW School of Medicine and director of the UW Alzheimer’s Disease Research Center. Dr. C. Dirk Keene is professor of laboratory ...